Literature DB >> 203850

Inhibition of angiotensin-converting enzyme for diagnosis of renal-artery stenosis.

R Re, R Novelline, M T Escourrou, C Athanasoulis, J Burton, E Haber.   

Abstract

To determine its utility as an aid in diagnosis of renovascular hypertension, we administered nonapeptide converting-enzyme inhibitor (CEI) (which inhibits conversion of angiotensin I to angiotensin II) (0.25 mg per kilogram) to 14 unselected hypertensive patients undergoing bilateral renal-vein catheterization. In seven (Group I) predominantly unilateral disease was discovered by angiography (renal-artery stenosis in six and hydronephrosis in one); in the remaining seven (Group II) no rennal-artery abnormality was found. In Group I, mean (+/- S.E.) ratio of involved to uninvolved renal-vein plasma renin activity (PRA) increased from 2.94 +/- 0.91 before to 8.36 +/- 2.94 after CEI (P less than 0.01). In Group II, the ratio (of the initially higher to the lower side) was 1.99 +/- 0.49 before and 1.17 +/- 0.07 after CEI (P greater 0.02). Post-CEI PRA was predicted by pretreatment PRA. Mean blood pressure fell in both groups after CEI, and the decrement was predicted by pre-CEI PRA. These data suggest that CEI can be of use at the time of renal-vein catheterization, serving to increase diagnostic accuracy by increasing the difference in PRA between the two sides when there is unilateral disease.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 203850     DOI: 10.1056/NEJM197803162981102

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  3 in total

Review 1.  ACE inhibitors in renovascular hypertension.

Authors:  S C Textor
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

Review 2.  The diagnosis of renovascular hypertension: the role of captopril renal scintigraphy and related issues.

Authors:  A Prigent
Journal:  Eur J Nucl Med       Date:  1993-07

3.  The renin/angiotensin system.

Authors:  M R Lee
Journal:  Br J Clin Pharmacol       Date:  1981-11       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.